JPRN-jRCTb030220456招募中1 期
Study on safety and efficacy of urinary continence by administration of autologous adipose tissue-derived stem cells for stress urinary incontinence after radical prostatectomy - S-SE-UC-ADSC-SUI-ARP
Hitoshi Masuda0 个研究点目标入组 10 人开始时间: 2022年11月24日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •1. Male patients suffering from stress urinary incontinence that is ineffective or inadequately effective in behavior therapy and drug therapy, or that drug therapy is difficult to carry out and continues for 1 year or more
- •after surgery.
- •2. Patients with stress urinary incontinence after radical radical prostatectomy, no recurrence or metastasis for 1 year or more after surgery, and prostate-specific antigen (PSA) of 0.1 ng / ml or less for 1 year or more after surgery.
- •3. Patients with a performance status (PS) score of 0 to 1 and no severe liver or renal dysfunction.
- •4. Patients over 18 years old at the time of consent acquisition.
- •5. Patients with an average daily urinary incontinence of 30 g or more and less than 400 g (mild to moderate) by a 24-hour pad test during the screening period.
- •6. Patients who are judged by the investigator or the investigator to be able to accurately record the urination diary.
- •7. Patients who have received sufficient explanation about this study and have obtained written consent at their own free will.
排除标准
- •Patients who fall under any of the following are excluded.
- •1. Patients with urge incontinence, overflow incontinence, functional incontinence or reflex incontinence, or patients with these incontinences.
- •2. Patients who underwent surgery with incisions in the urinary and genital organs within 6 months before obtaining consent.
- •3. Patients who started behavior therapy or drug therapy within 3 months before obtaining consent.
- •4. Patients with diabetes insipidus.
- •5. Patients who have received local radiation therapy for the lower urinary tract.
- •6. Patients who have received culture or non-culture ADSCs to the paraurethral region for the treatment of stress urinary incontinence.
- •7. Patients who received other cell therapy within 6 months before obtaining consent.
- •8. Patients who have participated in or are participating in other clinical trials within 3 months before obtaining consent.
- •9. Patients with lower urinary tract obstructive disease.
- •10. Patients with urinary tract stones (urinary tract stones, urinary tract stones, bladder stones, etc.), urinary tract infections (pyelonephritis, cystitis, etc.) or interstitial cystitis.
- •11. Patients with a history of recurrent urinary tract infection (onset more than 3 times within 6 months before obtaining consent).
- •12. Patients who have malignant neoplasms or have a history of malignant neoplasms within 5 years before obtaining consent, or patients who are judged to be possible malignant tumors by various tests (patients who meet the selection criterion 2. are excluded.)
- •13. Patients who have a life expectancy of less than one year at the time of consent acquisition.
- •14. Patients with or suspected of having a serious infection (infection requiring treatment by intravenous administration of antibacterial, antifungal or antiviral drugs).
- •15. Syphilis serum reaction positive (one of the following tests using cardiolipin as an antigen: RPR card test, aggregation method, glass plate method, automation method), HCV antibody positive, HBs antigen positive or HIV antibody positive, or HTLV at the time of screening test -1 antibody positive patients.
- •16. Patients with serious complications (liver disease, renal disease, heart disease, lung disease, blood disease, autoimmune disease, etc.).
- •17. Patients with a history of or complicated thromboembolism (cerebral infarction, myocardial infarction, deep venous thrombosis, pulmonary embolism, etc.).
- •18. Patients with a history of hypersensitivity to perflubutane preparations, lidocaine injection components or amide-type local anesthetics, or patients with allergies to casein, gelatin, eggs or egg products.
- •19. Patients who are considered to need administration of butyrophenone-based, phenothiazine-based antipsychotics, alpha blockers, catecholamines such as isoproterenol, and adrenergic agonists (except when used during fat aspiration) on the day of surgery.
- •20. Patients taking antiplatelet or anticoagulant drugs and having difficulty withdrawing.
- •21. Other patients who are judged to be inappropriate by the investigator or the subinvestigators.
研究者
相似试验
已完成
不适用
Effectiveness of an urinary incontinence program for Chinese elderly women in a community settingrinary incontinence in elderly womenUrological and Genital DiseasesUrinary incontinenceISRCTN62679410Department of Rehabilitation Sciences (Hong Kong)55
已完成
Unknown
Efficacy and Safety of Incontinence Device URINO in women with Stress Urinary Incontinence : Prospective, Multi-center, Single-arm, Pre-and-Post intervention, Confirmative TrialKCT0008369Rim Healthcare41
招募中
不适用
Randomised Study Assessing Urinary Continence following Robotic Radical Prostatectomy with or without an intraoperative 'RoboSling'.Urinary IncontinenceCancer - ProstateRenal and Urogenital - Other renal and urogenital disordersProstate CancerACTRN12618002058257Sydney Local Health District120
已完成
不适用
A randomized clinical trial of urinary incontinence in older women: cost-effectiveness of protocolized assessment and evidence-based treatmentNL-OMON31408Academisch Medisch Centrum246
尚未招募
Unknown
Effect of Constipation Relief Syrup to improve bowel movement, frequency of Defecation, & soft stool.CTRI/2023/08/056220sarbottam care limited